VMD Reports 58 Accidental Human Exposures to Librela, 18 to Solensia in UK Pharmacovigilance Data
核心洞察
The UK Veterinary Medicines Directorate (VMD (搜索)) has recorded 58 cases of accidental human exposure to Librela (bedinvetmab (搜索)), with 50 cases involving veterinary professionals.
A separate FOI response reveals 18 cases of accidental human exposure to Solensia (搜索) (frunevetmab (搜索)), 16 of which occurred in veterinary professionals.
The VMD (搜索) confirms no routine notification mechanism exists between itself and the MHRA, as the two agencies operate under distinct legal remits for veterinary versus human medicines.
The UK Veterinary Medicines Directorate (VMD (搜索)) has disclosed, through two Freedom of Information (FOI) responses published in March 2026, the number of accidental human exposure cases linked to two monoclonal antibody-based veterinary medicines: Librela (bedinvetmab (搜索)) and Solensia (搜索) (frunevetmab (搜索)). The data reveal a total of 58 accidental human exposures to Librela and 18 to Solensia, with the vast majority occurring among veterinary professionals.
Librela: 58 Accidental Human Exposures Recorded
According to FOI response FOI2026/00481, the VMD (搜索) holds records of 58 cases of accidental human exposure to Librela. Of these, 50 cases involved veterinary professionals—including veterinary surgeons, veterinary nurses, and veterinary students in training. One of these professional exposures occurred while a veterinary professional was driving and reached into their bag.
Six cases involved owner exposure while a veterinary professional was administering the product, and one case involved an owner administering the product at home. Only two cases specified the location of the incident: one occurred in a home environment, and one occurred in a car.
Solensia: 18 Accidental Human Exposures Recorded
A separate FOI response (FOI2026/00483) details 18 cases of accidental human exposure to Solensia (搜索). Of these, 16 cases occurred in veterinary professionals (veterinary surgeons or nurses). One case reported owner exposure but did not specify who administered the product, and one case reported that the owner was administering the injection. None of the Solensia cases specified where the incident took place.
Regulatory Framework and Inter-Agency Communication
The VMD (搜索) clarified in both responses that accidental exposure to veterinary medicines, including biologics, is monitored within its statutory pharmacovigilance system. Under the Veterinary Medicines Regulations, the VMD holds responsibility for adverse events in animals, people handling veterinary medicines, and the environment.
The Medicines and Healthcare products Regulatory Agency (MHRA), by contrast, regulates human medicines under separate legislation and operates the Yellow Card Scheme, which does not apply to veterinary medicinal products. The VMD (搜索) stated: "Because the regulators have distinct legal remits, reporting systems and data models, there is no mechanism or requirement for routine notification between the two agencies."
Guidance for Exposed Individuals
Both FOI responses highlight that the package leaflet for each product advises individuals who experience accidental exposure or adverse reactions to consult a doctor and to take the medicine container, label, or package leaflet with them. This enables the treating clinician to access the active substance information, precautionary statements, and first-aid advice exactly as authorised.
The VMD (搜索) further noted that more detailed product information, including the Summary of Product Characteristics (SPC) and the Public Assessment Report, is published on the VMD Product Information Database, where updates appear shortly after authorisation changes.